SMMT vs SNDX: fair value comparison
Summit Therapeutics Inc. and Syndax Pharmaceuticals, Inc. · Updated 2026-10-19
SMMT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SNDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SMMT currently ranks higher by quality score.
| SMMT | SNDX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $14.63 | $12.90 |
| 12-month range | $12.43–$26.38 | $12.90–$25.15 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #268 of 301 Healthcare | #269 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | High |
| Margin trend | Contracting | Stable |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: SMMT fair value analysis · SNDX fair value analysis